Harvard Bioscience, Inc. (NasdaqCM: HBIO)
Health Care · Life Sciences Tools & Services · US
$7.48
+12.40% today · +53.0% 1Y
Harvard Bioscience, Inc. (NasdaqCM: HBIO) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $34.05M and employs 328 people.
Over the last twelve months the share price has gained 53.0%, trading between 3.76 and 9.40.
Tweenvest scores Harvard Bioscience, Inc. across four factors: quality 49/100, value 57/100, growth 34/100. Its strongest factor is value.
HBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $34.05M
- Revenue (TTM)
- $87.81M
- P/E
- —
- EPS
- -2.35
- Dividend yield
- —
- Beta (5Y)
- 1.49
- 52-week high
- $9.40
- 52-week low
- $3.76
- Avg volume (3M)
- —
- Shares outstanding
- 4.55M
- Employees
- 328
- Next earnings
- —
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
- ISIN
- US4169062043
- Founded
- 1901
- Listed since
- Dec 7, 2000
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Thermo Fisher Scientific Inc.NYSE: TMO | $232.67B | $629.27 | +0.27% |
| Danaher CorporationNYSE: DHR | $153.85B | $218.85 | +1.36% |
| WuXi AppTec Co., Ltd.SHSE: 603259 | $72.12B | CN¥162.86 | -3.00% |
| Samsung Biologics Co.,Ltd.KOSE: A207940 | $51.75B | ₩1,551,000.00 | +0.19% |
| Lonza Group AGSWX: LONN | $51.61B | CHF592.20 | +1.09% |
| Agilent Technologies, Inc.NYSE: A | $44.91B | $159.00 | +1.73% |
| IQVIA Holdings Inc.NYSE: IQV | $42.77B | $259.82 | +1.47% |
| Waters CorporationNYSE: WAT | $40.35B | $410.70 | +1.49% |
Figures last refreshed Aug 18, 2026.